3 results
Approved WMOCompleted
To determine the effect size of PRM-151 relative to placebo in change from Baseline to Week 28 in mean FVC% predicted, pooling subjects on a stable dose of pirfenidone or nintedanib and subjects not on other treatment for IPF.
Approved WMOPending
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:• Reducing global disability in participants with acute ischemic stroke (AIS)
Approved WMOCompleted
5.1 Primary ObjectiveTo confirm the efficacy of glepaglutide in reducing PS volume in SBS patients.5.2 Secondary ObjectivesTo evaluate the efficacy of glepaglutide on other efficacy endpoints in patients with SBS.To evaluate the safety and…